• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Value Discussion in Cancer Care Escalates: NICE and Roche

Article

According to Sir Andrew Dillon, chief executive of NICE, the high price that Roche is demanding for Kadcyla is beyond the means of NHS to cover.

Sir Andrew Dillon, Nice chief executive says that the NHS cannot afford to pay Roche the high price it is demanding for its "miracle" breast cancer treatment. The drugs giant has responded by insisting that Nice is the only health body to conclude that Kadcyla is not good value for money.

Listen to the argument from both sides: http://bit.ly/1q0KdL5

Source: The Telegraph

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.